RC110 had and has excellent prospects, and I have explained the...

RC110 had and has excellent prospects, and I have explained the limitations of central line and the issues with peripheral line therapy. RC110 provided positive insight into clinical efficacy and cardioprotection in combination with clofarabine and fludarabine. The second sign that Bisantrene is paving a new trail for cancer synergy. The failing is only because a 20-year patent life through an improved formulation presents such a bigger, more achievable opportunity. I could have seen this sooner, but share price movements of a company certainly don't reflect value in this game.

The issue here, my man, is that I post on IMU because I care about Australian investors. It troubles me that investors can be mislead by companies and I play an active role in mediating that. I can't control if you respond to what I say emotionally. You are likely posting here because you are upset at what I have said and feel it justifiable revenge. We are different people.